India, July 24 -- Annexon Inc. (ANNX) today announced that it has achieved a key clinical milestone by completing enrollment in its phase III trial of Vonaprument for dry age-related macular degeneration with geographic atrophy.
The phase III trial, dubbed ARCHER II, has enrolled more than 630 patients who will be randomized 2:1 to receive a monthly dose of Vonaprument or a sham procedure. The primary endpoint is the prevention of a loss of 15 or more letters in best corrected visual acuity (BCVA), which represents three lines on the standard Early Treatment of Diabetic Retinopathy Study (ETDRS) eye chart.
Vonaprument previously demonstrated significant vision preservation based upon best corrected visual acuity (BCVA) and low luminance v...